PDCD1 and melanoma: With respect to PD-1/PD-L1 inhibition, there are fewer circulating Treg cells in melanoma patients treated with ICI, and mice deficient for PD-1/PD-L1 develop auto-antibodies to various normal endogenous murine proteins [22,23,24,25,26].